Our data also illustrated the relevance of HLA class I as an inhibitory immune-checkpoint for NK cells in breast cancer, prompting follow-up studies to enhance NK cell responses by the combination of ADCC-triggering antibodies and strategies to interfere with the interaction between HLA class I and KIR/NKG2A. This evidence concerns the gene KIR3DL1 and breast carcinoma.